Earning Analysis
Welcome to our in-depth analysis of (NARI) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q3 | 2024-10-28 | After Hours | -0.12 | -0.13 | -8.33 | 150.67M | 153.39M | +1.80 | +15.55 | +14.97 |
| FY2024Q2 | 2024-07-30 | - | -0.16 | -0.41 | -156.25 | 143.80M | 145.82M | +1.40 | -2.14 | -13.30 |
| FY2024Q1 | 2024-04-30 | - | -0.11 | -0.26 | -136.36 | 137.76M | 143.19M | +3.95 | -1.61 | +10.25 |
| FY2023Q4 | 2024-02-28 | - | 0.01 | 0.05 | +400.00 | 132.09M | 132.09M | +0.01 | -0.02 | -29.95 |
| FY2023Q2 | 2023-08-02 | - | -0.14 | 0.04 | +128.57 | 116.72M | 119.01M | +1.95 | -1.75 | +9.24 |
| - | 2023-05-03 | - | -0.23 | -0.04 | +82.61 | - | - | - | +4.88 | +16.43 |
| - | 2023-02-27 | - | -0.17 | -0.11 | +35.29 | - | - | - | +1.77 | -0.92 |
| - | 2022-11-02 | - | -0.24 | -0.19 | +20.83 | - | - | - | -2.30 | -8.86 |
| - | 2022-08-03 | - | -0.23 | -0.19 | +17.39 | - | - | - | +0.93 | +1.48 |
| - | 2022-05-04 | - | -0.08 | -0.06 | +25.00 | - | - | - | +4.54 | -29.23 |
NARI Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, reported performance for FY2024Q3, announced on 2024-10-28. The company achieved an EPS of -0.13, compared to analyst estimates of -0.12 by -8.33% . Revenue for the quarter reached 153.39M compared to expectations of 150.67M by 1.80% .
The stock price reacted with a 15.55% one-day change and a 14.97% five-day change following the earnings release. These movements reflect market reaction in growth trajectory and strategic initiatives.
NARI Earnings Forecast
Looking ahead, (NARI) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2024/Q4 project quarter revenue of 160.70M and an EPS of 0.01.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2024 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2024, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between NARI's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2024
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q4 2024
No Change
0.00%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2024
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2024:603.05M
--
EPS Estimate-Annual FY 2024:-0.72
—
Stock Price79.97
NARI Revenue and EPS Performance: A Historical Perspective
revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q3 (2024-10-28,After Hours):
EPS: -0.13 (Actual) vs.-0.12 (Estimate) (-8.33%)
Revenue: 153.39M (Actual) vs. 150.67M (Estimate) (1.80%)
Price Reaction: 15.55%(1-Day), 14.97%(5-Day)
FY2024Q2 (2024-07-30,):
EPS: -0.41 (Actual) vs.-0.16 (Estimate) (-156.25%)
Revenue: 145.82M (Actual) vs. 143.80M (Estimate) (1.40%)
Price Reaction: -2.14%(1-Day), -13.30%(5-Day)
FY2024Q1 (2024-04-30,):
EPS: -0.26 (Actual) vs.-0.11 (Estimate) (-136.36%)
Revenue: 143.19M (Actual) vs. 137.76M (Estimate) (3.95%)
Price Reaction: -1.61%(1-Day), 10.25%(5-Day)
Earnings Reaction
The chart below shows how NARI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NARI sees a +1.83% change in stock price 10 days leading up to the earnings, and a +1.86% change 10 days following the report. On the earnings day itself, the stock moves by +0.17%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2024, the stock changed 15.55% on the day following the earnings release and then changed by 25.35% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Summary
Neutral
2024-10-29
The earnings call presents mixed signals. Financial performance shows strong revenue growth but also increased operating losses, which is concerning. The Q&A section reveals stable market health and growth potential, but management's vague responses on certain topics may raise investor concerns. The lack of a shareholder return plan and declining gross margins also contribute to a neutral outlook. However, the raised annual revenue guidance and robust growth in emerging therapies offer positive aspects, balancing the negative elements. Given the company's market cap, the stock price is likely to remain stable over the next two weeks.
Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Summary
Positive
2024-07-31
The earnings call highlighted strong financial performance, including record revenue growth and international expansion. Despite increased operating losses and a DOJ inquiry, optimistic guidance and a raised revenue forecast signal confidence. The Q&A session reinforced positive sentiment, especially with the expected impact of PEERLESS data. The lack of a shareholder return plan is a minor downside, but overall, the market is likely to react positively, considering the company's small-cap nature.
People Also Watch
RELY
Remitly Global Inc
19.970
USD
+2.94%
TIGO
Millicom International Cellular SA
44.010
USD
+1.15%
GDS
GDS Holdings Ltd
33.920
USD
-6.58%
AVT
Avnet Inc
54.760
USD
+2.66%
ALGM
Allegro Microsystems Inc
31.860
USD
-0.09%
VVV
Valvoline Inc
39.870
USD
+2.97%
KRC
Kilroy Realty Corp
38.730
USD
+2.19%
MATX
Matson Inc
109.910
USD
+1.72%
TGTX
TG Therapeutics Inc
27.870
USD
+2.77%
RIOT
Riot Platforms Inc
11.590
USD
+1.31%
FAQ
What were the key highlights of NARI’s latest earnings report for FY2024Q3?
NARI reported its FY2024Q3 earnings on 2024-10-28, showcasing a revenue of 153.39M against an estimate of 150.67M, resulting in a 1.8% surprise. The EPS was -0.13, surpassing the expected -0.12 by -8.33% . The stock experienced a 15.55% price change on the earnings day and a 14.97% change over the next five days, reflecting market reactions to the results.
How did NARI’s stock price react after the FY2024Q3 earnings release?
What are the revenue and EPS estimates for NARI for 2024/Q4?
How does NARI’s stock price correlate with earnings forecast revisions?
What should investors expect from NARI’s next earnings report?